A new experimental vaccine against Ebola has proven 100% effective against the virus in clinical trials, as steps continue to fully eradicate the disease.

The results of the trial were published in a study in the  Lancet medical journal. It was titled “Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial,” and led by Dr. Ana Maria Henao Restrapo.

Over 11,300 people died during an outbreak of the disease between 2013 and 2015. The vaccine was first tested in Guinea, and very promising preliminary results prompted the World Health Organization to allow a widespread administration.

Over 11,000 people have been administered and none of them have gotten the virus, according to the New York Times. The vaccine, rVSV-EBOV,  is licensed by US firm Merck, who have promised to have 300,000 doses ready should an outbreak occur again.

“While these compelling results come too late for those who lost their lives during West Africa’s Ebola epidemic, they show that when the next Ebola outbreak hits, we will not be defenseless,” said WHO assistant director-general Dr. Marie-Paule Kieny. “The world can’t afford the confusion and human disaster that came with the last epidemic.”

The vaccine however works only on Zaire Ebolavirus, one of five strands of Ebola currently known. Still, its way better than not having a cure.

“Ebola left a devastating legacy in our country,” says Director of the National Agency for Health Security in Guinea, KeÏta Sakoba. “We are proud that we have been able to contribute to developing a vaccine that will prevent other nations from enduring what we endured.”

This is certainly great news!